Compare AGPU & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | ACRV |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 74.0M |
| IPO Year | 2008 | 2022 |
| Metric | AGPU | ACRV |
|---|---|---|
| Price | $10.68 | $2.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 561.9K | 382.5K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $125,284.00 | N/A |
| Revenue This Year | $12,476.23 | N/A |
| Revenue Next Year | $55.17 | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $1.27 |
| 52 Week High | $10.92 | $3.56 |
| Indicator | AGPU | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 70.10 |
| Support Level | $6.26 | $2.14 |
| Resistance Level | $10.86 | $2.48 |
| Average True Range (ATR) | 1.02 | 0.12 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 88.39 | 84.58 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.